Medicus Pharma Ltd. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDCX research report →
Range $1 – $1
Price Chart
About the company
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
- CEO
- Raza Bokhari
- IPO
- 2024
- Employees
- 16
- HQ
- West Conshohocken, PA, CA
Get TickerSpark's AI analysis on MDCX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.63M
- P/E
- -0.02
- Fwd P/E
- 0.16
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.14
- EV/EBITDA
- -0.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1594.83%
- ROIC
- -388.27%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,351,132
- Net Income
- $-25,366,424-127.4%
- EPS
- $-98.00-184.1%
- OCF Growth
- -122.3%
- FCF Growth
- -122.3%
- 52W High
- $114.00
- 52W Low
- $1.06
- 50D MA
- $4.56
- 200D MA
- $18.52
- Beta
- -0.61
- RSI (14)
- 20
- Avg Volume
- 115.46K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medicus highlighted a major strategic shift toward precision oncology, with Pfizer-backed CD228V taking priority while SkinJect and Teverelix advance in parallel under a tighter capital plan.· November 9, 2026
- Medicus said it is repositioning around CD228V, an ADC licensed from Pfizer with worldwide development/manufacturing/commercialization rights and a $2 million Pfizer development contribution.
- Management reiterated a goal of >30% objective response rate in melanoma for CD228V, but said this still needs to be proven in trials.
- SkinJect now has a nonbinding LOI for a proposed business combination at a $135 million pre-money enterprise valuation, with completion targeted for 1H 2027.
- Teverelix is being reshaped for partnering, with a smaller acute urinary retention study design (126 patients vs. 390 originally) and an advanced prostate cancer program awaiting FDA feedback.
- CFO said 9M 2026 operating expenses rose to $34.5 million and net loss widened to $35.9 million, but management expects operating expenses to decline substantially in coming quarters.
For the 9 months ended September 30, 2026, Medicus raised approximately $42.5 million through equity and secured debt financing, net of issuance costs; after approximately $6.4 million of debt repayments, net cash provided by financing activities was $36.2 million. Operating expenses were $34.5 million versus $26.6 million a year earlier, including $15 million of G&A, $9.6 million of R&D, and a $10 million acquired IPR&D charge for CD228V. Net loss was $35.9 million versus $27.3 million. In the third quarter, operating expenses were $14.5 million versus $15.4 million, and net loss was $15.2 million versus $16 million. Cash, cash equivalents and restricted cash were $13.1 million at September 30, 2026, including $5 million in cash and cash equivalents and $8.1 million in restricted cash. Total liabilities were $25 million. Management did not provide formal next-quarter or full-year financial guidance, but said it anticipates a substantial reduction in operating expenses in the coming quarters and highlighted continued capital allocation toward CD228V, SkinJect readiness, and Teverelix partnering.
Raza Bokhari framed the quarter as a transformation period, saying Medicus is becoming a precision oncology-led biotechnology company with CD228V as the lead asset. His tone was constructive but cautious: he emphasized a capital-efficient strategy, selective milestone advancement, and the need to earn future value through clinical evidence rather than broad spending. He also stressed that SkinJect and Teverelix remain part of the portfolio, but with development tied more tightly to partnerships, financing, and regulatory milestones.
Carolyn Bonner focused on financing, expense structure, and balance sheet priorities. She said the company raised approximately $42.5 million over 9M 2026, had $13.1 million of combined cash, cash equivalents and restricted cash at September 30, and reported $25 million of total liabilities, mainly tied to the Streeterville Capital debenture. She also noted the $10 million acquired IPR&D charge related to CD228V, and said the company expects a substantial reduction in operating expenses in the coming quarters while directing incremental capital to CD228V and preserving Teverelix and SkinJect value.
Analysts asked when the next clinical and regulatory milestones for CD228V would occur; management said it is still assimilating the program, but is using an existing clinical foundation, manufacturing knowledge and prior regulatory experience to build an efficient development plan and reach the next meaningful clinical decision point quickly. On SkinJect, management said it will continue advancing SKNJCT-005 in parallel and does not plan to wait for the SPAC transaction to close before progressing the program. On Teverelix, management said it is seeking “all of the above” in partnerships—global, regional or otherwise—while refining the development plan, awaiting FDA feedback on the advanced prostate cancer program, and completing CMC work that is expected to make product available in the first quarter of next year.
The bullish case from the call is that Medicus now has a clearer lead asset with a major pharma partner, retained worldwide rights, and a focused development strategy centered on a defined melanoma population. Management pointed to existing human data, the vedotin platform, and a potential >30% response-rate benchmark as reasons for optimism, while also describing SkinJect and Teverelix as value-creation opportunities that can be advanced with limited near-term spend.
The main risks are that CD228V remains early and the >30% response-rate target is only management’s expectation, not yet demonstrated in trials. SkinJect’s transaction is still nonbinding and may not close, Teverelix depends on FDA feedback and partner interest, and management flagged execution issues in CMC and the need to secure future financing and partnerships to fund development.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.4%
- Shares Outstanding
- 1.43M
- Float Shares
- 1.05M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Interchange Capital Partners, LLC | 2.12M | ▲ 538.04K |
| Private Advisor Group, LLC | 230.06K | ▲ 230.06K |
| Jane Street Group, LLC | 181.61K | ▼ 152.06K |
| Corient Private Wealth LP | 100.00K | ▲ 100.00K |
| Sterling Investment Advisors, Ltd. | 100.00K | 0 |
| Ubs Group AG | 81.71K | ▲ 81.71K |
| Commonwealth Equity Services, LLC | 73.86K | ▲ 21.22K |
| May Hill Capital, LLC | 50.62K | 0 |
| Stifel Financial Corp | 30.00K | 0 |
| Susquehanna International Group, Llp | 28.90K | ▼ 2.56K |
| Jpmorgan Chase & Co | 25.66K | ▲ 36 |
| Citadel Advisors LLC | 25.10K | ▲ 7.28K |
Held by 1 ETFs
Biggest fund positions in MDCX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Smith Andrew Alasdair | other | 14,534 |
| Nov 13, 26 | Mehmud Faisal | other | 14,534 |
| Nov 13, 26 | May Sara R. | other | 5,813 |
| Nov 13, 26 | MAHAFFY PATRICK J | other | 14,534 |
| Nov 13, 26 | Kaiser Larry | other | 14,534 |
| Nov 13, 26 | Ciaruffoli Robert J. | other | 72,674 |
| Nov 13, 26 | Brennan Edward J. | other | 14,534 |
| Nov 13, 26 | Bonner Carolyn F. | other | 29,069 |
| Nov 13, 26 | Bokhari Raza | other | 436,046 |
| Sep 4, 26 | Smith Andrew Alasdair | other | 735,294 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDCX coverage
Recent articles, reports, and earnings notes.
No research on MDCX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDCX report →Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing
globenewswire.com · Nov 19
Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange
globenewswire.com · Nov 16
Medicus Pharma Ltd. (MDCX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Medicus Pharma to Present at BIO-Europe 2026
globenewswire.com · Nov 5
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026
globenewswire.com · Nov 4
Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing
globenewswire.com · Nov 4
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
globenewswire.com · Oct 27
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
globenewswire.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.